Pro-inflammatory and pro-apoptotic factors in heart failure

  • Laura Agnoletti
  • Laura Comini
  • Giuseppina Gaia
  • Salvatore Curello
  • Roberto Ferrari
Part of the Basic Science for the Cardiologist book series (BASC, volume 5)


Congestive heart failure (CHF) is a final common pathway of different etiologies that results in a compensatory hypertrophy of myocytes which increase their size and the expression of contractile and other proteins normally expressed only during foetal development (1).


Major Histocompatibility Complex Dilate Cardiomyopathy Idiopathic Dilate Cardiomyopathy Congestive Heart Failure Patient Adenine Nucleotide Translocator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chien KR, Zhu H, Knowlton KU et al. Transcriptional regulation during cardiac growth and development. Annu Rev Phisiol 1993;55, 77–95.CrossRefGoogle Scholar
  2. 2.
    Katz AM. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994; 121:363–71.PubMedGoogle Scholar
  3. 3.
    Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation 1994;89:2421–32.PubMedGoogle Scholar
  4. 4.
    Limas C. Autoimmunity in dilated cardiomyopathy and the major histocompatibility complex. Int J Cardiol 1996, 54:113–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Andreassen AH, Nordoy I, Siminsens S, Ueland T, Muller F, Froland SS, Guliestad L, Aukrust P. Levels of circulating adeshion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998, 81(5):604–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Toyozaki T, Saito T, Takano H, et al. Expression of intracellular adhesion molecule-l on cardiac myocyte for myocarditis before and during immuno-suppresive therapy. Am J Cardiol 1993;72:441–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Eckstein R, Mempel W, Boite HD. Reduced suppressor cell activity in congestive cardiomyopathy and in myocarditis. Circulation 1982;65:1224–9.PubMedGoogle Scholar
  8. 8.
    Anderson JL, Carlquist JF, Hammond EH. Deficient natural killer cell activity in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:755–8.CrossRefGoogle Scholar
  9. 9.
    Hwang S, Harris TJ, Wilson NW, Maisei AS. Immune function in patients with chronic stable congestive heart failure. Am Heart J 1993; 125:1651–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Rönnblom LE, Forsberg H, Evrin P. Increased level of HLA-DR-expressing T lymphocytes in peripheral blood from patient with idiopathic dilated cardiomyopathy. Cardiology 1991;78:161–7.PubMedGoogle Scholar
  11. 11.
    Caforio ALP, Stewart JT, Bonifacio E et al. Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relative for autoimmunity? J Autoimmun 1990;3:187–200.PubMedCrossRefGoogle Scholar
  12. 12.
    Koike S. Immunological disorders in patients with dilated cardiomyopathy. Jpn Heart J 1989, 30:799–807.PubMedGoogle Scholar
  13. 13.
    Limas CJ, Goldemberg IF, Limas C. Soluble inter)eukine-2 receptor levels in patients with dilated cardiomyopathy. Circulation 1995;91:631–43.PubMedGoogle Scholar
  14. 14.
    Friedberg CK. Diseases of the heart. Philadelphia, PA: Saunders, 1996, p 233.Google Scholar
  15. 15.
    Pittman JC, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 1964;271:453–60.PubMedGoogle Scholar
  16. 16.
    Levine B, Kaiman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of necrosis factor in severe chronic heart failure. N Engl J Med 1990;323. 236–41.PubMedGoogle Scholar
  17. 17.
    Ware CF, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 1996;60:47–55.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang CY, Mayo MW, Baldwin ASJ. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NFkB [see comments]. Science 1996;274:784–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996;148:141–9.PubMedGoogle Scholar
  20. 20.
    Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996; 12(1): 1–9.PubMedGoogle Scholar
  21. 21.
    Tracey KJ. The acute and chronic pathophysiological effects of TNF: mediation of septic shock and wasting. In: Beutler B, editor. Tumor necrosis factors: the molecules and their emerging role in medicine. New York, NY: Raven, 1992:255–73.Google Scholar
  22. 22.
    Van Deuren M, Dofferhoff ASM, Van der Meer JW. Cytokines and the response to infection. J Pathol 1992;168:349–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Ferrari R, Bachetti T, Confortini R et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 1995;92:1479–86.PubMedGoogle Scholar
  24. 24.
    Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Tsutamoto T, Hisanaga T Wada A, Maeda Y, Fukai D. Plasma concentration of interIeukin-6 as a marker of prognosis in patients with chronic congestive heart failure (Abstr). Circulation 1994;90:1–381.Google Scholar
  26. 26.
    Kubota T, McTiernan CF, Frye CS et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Cir Res 1997, 81:627–35.Google Scholar
  27. 27.
    Bryant D, Becker L, Richardson J et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375–81.PubMedGoogle Scholar
  28. 28.
    Bozkurt B, Kribbs SB, Clubb FJ et al. Pathophysiologiaelly relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382–91.PubMedGoogle Scholar
  29. 29.
    Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995;95:677–85.PubMedGoogle Scholar
  30. 30.
    Krown KA, Page MT, Nguyen C et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. J Clin Invest 1996;98:2854–65.PubMedGoogle Scholar
  31. 31.
    Comini L, Bachetti T, Agnoletti L, Gaia G, Curello S, Milanesi B, Volterrani M, Parrinello G, Ceconi C, Giordano A, Corti A, Ferrari R. Induction of functional inducible nitric oxide sinthase in monocyte of patients with congestive heart failure: link with tumor necrosis factor-α. European Heart J, in press.Google Scholar
  32. 32.
    Agnoletti L, Curello S, Bachetti T, Malacame F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, Ferrari R. Serum from patients with severe heart failure down-regulate eNOS and is proapoptotic: role of the tumor necrosis factor-α. Circulation, in press.Google Scholar
  33. 33.
    Tanaka M, Ito H, Adachi S et al. Ipoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rad cardiomyocytes. Circ Res 1994;75:426–33.PubMedGoogle Scholar
  34. 34.
    Nishigaki K, Minatoguchi S, Seishima M, asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S, Fujiwara H. Plasma Fas ligand, an inducer of apoptosis and plasma soluble Fas, an inhibitor of apoptosis in patients with chronic congestive heart failure. J Am Coll Cardiol 1997;29(6): 1214–20.PubMedCrossRefGoogle Scholar
  35. 35.
    Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A Rose NR. Interleukin-1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant BIO.A mice. J Exp Med 1992;175:1123–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Blum A, Scarovsky S, Rehavia E, Shohat B. Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interIeukin-2 receptor in acute myocardial infarction. Am Heart J 1994;127:1226–30.PubMedCrossRefGoogle Scholar
  37. 37.
    Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Marriott JB, Goldman JH, Keeling PJ, Baig M K, Dalgleish AG, McKenna WJ. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 1996;75:287–90.PubMedGoogle Scholar
  39. 39.
    Schulze K, Becker BF, Schauer R, Schuitheiss HP. antibodies to ADP-ATP carries-an auto-antigen in myocarditis and dilated cardiomyopathy-impair cardiac function. Circulation 1990:81:959–69.PubMedGoogle Scholar
  40. 40.
    Limas CJ, Limas C. Immune-mediated modulation of b-adrenoceptor function in human dilated cardiomyopathy. Clin Immunopathol 1993;68:204–7.CrossRefGoogle Scholar
  41. 41.
    Podlowski S, Luther HP, Morwinski R, Müller J, Wallukat G. Agonistic anti-βl-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the βl-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 1998;98:2470–6.PubMedGoogle Scholar
  42. 42.
    Matsui S, Fu M. Characteristic distribution of circulating auto-antibodies against G-protein coupled cardiovascular receptors in patients with idiopathic dilated and hypertrophic cardiomyopathy. int J Cardiol 1996;54:143–7.PubMedCrossRefGoogle Scholar
  43. 43.
    McNamara D, Di-Salvo T, Mathier M, Keck S, Semigran M, Dec GW. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosoppression. J Heart Lung Transplant 1996; 15:506–15.PubMedGoogle Scholar
  44. 44.
    Carlquist JF, Menlove RL, Murray MB et al. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Circulation 1991;83:515–22.PubMedGoogle Scholar
  45. 45.
    Fowles RE, Bieber CP, Stinson EB. Defective in vitro suppressor cell function in idiopathic congestive cardiomyopathy. Circulation 1979;59:483–91.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Laura Agnoletti
    • 1
  • Laura Comini
    • 1
  • Giuseppina Gaia
    • 1
  • Salvatore Curello
    • 1
  • Roberto Ferrari
    • 1
  1. 1.Salvatore Maugeri FoundationBrescia, and University of FerraraItaly

Personalised recommendations